Tiger Brokers

  • Quotes
  • Invest
  • Pricing
  • Download
  • Rewards
  • Help
  • TigerAI
  • Institution
    • Wealth and asset manager
    • Proprietary trading institutions
    • Introducing brokers
    • Third-party service provider
    • Esop
  • About
    • About us
    • Newsroom
    • Awards
  • LOGIN
  • SIGN UP
US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

11.29
-0.8790-7.22%
Volume:1.21M
Turnover:14.05M
Market Cap:863.97M
PE:-7.85
High:12.05
Open:12.03
Low:11.28
Close:12.17
52wk High:14.00
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:1.90
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:6.85
PE(LYR):-15.66

Loading ...

OverviewCompanyNewsFilings

Insider Purchases Worth US$3.00m See Losses As Candel Therapeutics Market Value Drops To US$352m

Simply Wall St.
·
Mar 31

Candel Therapeutics Is Maintained at Buy by Citigroup

Dow Jones
·
Mar 18

Candel Therapeutics Inc : Citigroup Raises Target Price to $26 From $22

THOMSON REUTERS
·
Mar 18

U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks

Reuters
·
Mar 18

CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target

TIPRANKS
·
Mar 17

Candel Therapeutics publishes corporate presentation on its viral immunotherapy cancer pipeline

Reuters
·
Mar 17

BRIEF-Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec

Reuters
·
Mar 17

Candel Therapeutics Inc: Phase 3 Pivotal Study Planned for Initiation in Q2 2026

THOMSON REUTERS
·
Mar 17

Candel Therapeutics Inc: Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec

THOMSON REUTERS
·
Mar 17

Candel Therapeutics reports 25.4-month median overall survival and 50% 24-month survival in CAN-2409 phase 2a NSCLC trial

Reuters
·
Mar 17

Analyst Rate

Buy
Buy
88.89%
Hold
11.11%
Sell
0.00%

Corporate Actions

Financial Report Announcement
Aug 13, 2026 Pre-MKt
Financial Report Announcement
May 14, 2026 Pre-MKt
Financial Report Announcement
Mar 12, 2026 Pre-MKt
Financial Report Announcement
Nov 13, 2025 Pre-MKt
Financial Report Announcement
Aug 14, 2025 Pre-MKt

Dividend History

no data

No relevant data is available

Valuation Analysis

-8.46
Current
-5.99
Sector Average
17.58%
Historical Percentile
P/E[TTM]
+1 STD
Average
-1 STD
Current
-8.46
Maximum
-0.77
+1 STD
-1.76
Minimum
-16.57
-1 STD
-10.22
Average
-5.99

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10
     
     
     
     
Company Name:
Tiger Trade Technology Pte. Ltd.
Email Address:
dpo@itiger.com
User Agreement|Privacy Policy

Copyright © Tiger Trade Technology Pte. Ltd.

Product offerings in different jurisdictions may vary.

Information contained on this website is general in nature and does not take into account of your investment objectives, financial situation and specific needs. It should not be regarded as an offer to sell, asolicitation to buy, a recommendation or endorsement for any financial product, nor does it constitute an investment forecast, investment return commitments, investment suggestions or other practical operating opinions. Information contained on this website is for reference only and past performance should not be construed as future performance. Investment involves risks. Before you make an investment decision, you should carefully judge and screen whether the information contained on this website is appropriate for your needs, goals and circumstances.

We strive but cannot guarantee the accuracy, completeness, reliability and timeliness of all information on this website, and we are not responsible for any losses caused by the use of or reliance on relevant information.

The products and services offered on the website are subject to applicable laws, regulations and relevant agreements. Please carefully read and agree to the agreements before using our products and services.